Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Shield Therapeutics ( (GB:STX) ).
Shield Therapeutics has amended its senior secured debt financing, enhancing its financial position by increasing available funds to $50 million, with $15 million earmarked for future mergers and acquisitions. The revised terms, achieved through collaboration with SWK Holdings and Runway Growth Finance, lower debt costs and extend the interest-only period, providing Shield with greater flexibility to pursue growth opportunities and strengthen its market position in the pharmaceutical industry.
The most recent analyst rating on (GB:STX) stock is a Hold with a £8.50 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.
Spark’s Take on GB:STX Stock
According to Spark, TipRanks’ AI Analyst, GB:STX is a Neutral.
The overall stock score is primarily impacted by the company’s weak financial performance, characterized by negative profitability and financial distress. While technical indicators show some positive momentum, valuation concerns due to negative earnings and lack of dividends further weigh down the score.
To see Spark’s full report on GB:STX stock, click here.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency through its innovative product, ACCRUFeR®/FeRACCRU® (ferric maltol). The company has established a significant presence in the U.S. market through a collaboration with Viatris and has licensed its product to various partners across Europe, Canada, China, and other regions. ACCRUFeR® is the first FDA-approved oral iron therapy for iron deficiency and anemia, offering a novel mechanism of absorption and a well-tolerated treatment option.
Average Trading Volume: 3,587,723
Technical Sentiment Signal: Hold
Current Market Cap: £103M
For detailed information about STX stock, go to TipRanks’ Stock Analysis page.